Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Rubius Therapeutics, Inc. (RUBY : NSDQ)
 
 • Company Description   
Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States.

Number of Employees: 269

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.08 Daily Weekly Monthly
20 Day Moving Average: 1,619,827 shares
Shares Outstanding: 90.21 (millions)
Market Capitalization: $97.43 (millions)
Beta: 2.84
52 Week High: $29.06
52 Week Low: $0.96
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.28% -5.70%
12 Week -78.44% -76.30%
Year To Date -88.84% -86.37%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
399 BINNEY STREET SUITE 300
-
CAMBRIDGE,MA 02139
USA
ph: 617-679-9600
fax: -
ir@rubiustx.com http://www.rubiustx.com
 
 • General Corporate Information   
Officers
Pablo J. Cagnoni - Chief Executive Officer
David R. Epstein - Chairman
Jose Carmona - Chief Financial Officer
Noubar B. Afeyan - Director
Francis Cuss - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 78116T103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 90.21
Most Recent Split Date: (:1)
Beta: 2.84
Market Capitalization: $97.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.13 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.72
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -13.73%
vs. Previous Quarter: 4.92%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -103.09
12/31/21 - -81.21
09/30/21 - -78.24
ROA
03/31/22 - -61.58
12/31/21 - -52.22
09/30/21 - -49.71
Current Ratio
03/31/22 - 6.23
12/31/21 - 6.63
09/30/21 - 8.74
Quick Ratio
03/31/22 - 6.23
12/31/21 - 6.63
09/30/21 - 8.74
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.49
12/31/21 - 1.99
09/30/21 - 2.49
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.57
12/31/21 - 0.43
09/30/21 - 0.34
Debt-to-Capital
03/31/22 - 36.19
12/31/21 - 29.87
09/30/21 - 25.30
 

Powered by Zacks Investment Research ©